Viewing Study NCT02468661

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 12:57 PM
Ignite Modification Date: 2026-04-30 @ 1:13 AM
Study NCT ID: NCT02468661
Status: TERMINATED
Last Update Posted: 2020-02-24
First Post: 2015-06-01
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Non-Small Cell Lung Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Non-Small Cell Lung Cancer View
None NSCLC View
None INC280 View
None erlotinib View
None advanced/metastatic non-small cell lung cancer View
None EGFR mutation View
None cMET amplification View
None EGFR tyrosine kinase inhibitor (EGFR TKI) View